secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2024-12-17T23:59:59+00:00
Accession:  0001650664-24-000144
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
LLM model:  deepseek-v4-flash:cloud@v2

Editas Medicine CMO Baisong Mei steps down; separation terms outlined
---------------------------------------------------------------------

- Baisong Mei to step down as CMO effective Dec 31, 2024; transition period ends Jan 31, 2025.
- Separation agreement provides 12 months base salary, COBRA contributions, and potential 2024 bonus.
- Vested stock option exercise extended to Dec 31, 2025; unvested RSUs vest through 90 days post-separation.
- Agreement includes standard release, non-disparagement, and confidentiality clauses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000144/0001650664-24-000144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000144/edit-20241216.htm
  HTML page:      https://secwatch.observer/filing/0001650664-24-000144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer